Upgrade to SI Premium - Free Trial

EyePoint Pharmaceuticals (EYPT)

4.58 +0.01 (0.22%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (11/4/26)

Latest Headlines

TD Cowen Downgrades EyePoint Inc. (EYPT) to Hold September 2, 2026 2:04 AM - StreetInsider Form 4 EyePoint, Inc. For: Aug 20 Filed by: Elston George August 24, 2026 4:11 PM - SEC Filing Form 4 EyePoint, Inc. For: Aug 18 Filed by: Zaderej Karen L. August 18, 2026 4:09 PM - SEC Filing EyePoint Pharmaceuticals (EYPT) call put ratio 1.4 calls to 1 put as share price up 8.9% August 18, 2026 1:27 PM - StreetInsider Chardan Downgrades EyePoint Inc. (EYPT) to Neutral August 18, 2026 8:11 AM - StreetInsider H.C. Wainwright Downgrades EyePoint Inc. (EYPT) to Neutral August 18, 2026 6:09 AM - StreetInsider RBC Capital Downgrades EyePoint Inc. (EYPT) to Sector Perform August 18, 2026 2:52 AM - StreetInsider EyePoint Inc. (EYPT) PT Lowered to $48 at Laidlaw August 17, 2026 3:24 PM - StreetInsider Guggenheim Reiterates Buy Rating on EyePoint Inc. (EYPT) August 17, 2026 1:01 PM - StreetInsider JPMorgan Downgrades EyePoint Inc. (EYPT) to Neutral August 17, 2026 12:51 PM - StreetInsider EyePoint Inc. (EYPT) PT Lowered to $8 at Jefferies August 17, 2026 12:31 PM - StreetInsider Stifel on EyePoint Inc. (EYPT): 'we think these data bode well for LUCIA (expected October) barring another unusual asymmetry' August 17, 2026 12:07 PM - StreetInsider Cantor Fitzgerald Downgrades EyePoint Inc. (EYPT) to Neutral August 17, 2026 9:30 AM - StreetInsider Form 8-K EyePoint, Inc. For: Aug 17 August 17, 2026 8:51 AM - SEC Filing Citi cuts EyePoint price target to $17 from $35, keeps Buy, stock down 67% August 17, 2026 8:41 AM - StreetInsider EyePoint's DURAVYU misses primary endpoint in wet AMD trial August 17, 2026 7:01 AM - StreetInsider EyePoint Announces Topline Data from LUGANO, the First of Two Pivotal Phase 3 Clinical Trials for DURAVYU™ 2.7mg in Wet AMD August 17, 2026 7:00 AM - Globe NewsWire EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) August 14, 2026 4:33 PM - Globe NewsWire Form SCHEDULE 13G/A EyePoint, Inc. Filed by: Cormorant Asset Management, LP August 14, 2026 2:03 PM - SEC Filing Form SCHEDULE 13G EyePoint, Inc. Filed by: Adage Capital Management, L.P. August 12, 2026 12:02 PM - SEC Filing EyePoint Inc. (EYPT) PT Lowered to $27 at H.C. Wainwright August 6, 2026 6:55 AM - StreetInsider Form S-8 EyePoint, Inc. August 5, 2026 4:24 PM - SEC Filing Form 10-Q EyePoint, Inc. For: Jun 30 August 5, 2026 4:07 PM - SEC Filing Form 8-K EyePoint, Inc. For: Aug 05 August 5, 2026 7:06 AM - SEC Filing EyePoint Pharmaceuticals (EYPT) Misses Q2 EPS by 15c August 5, 2026 7:05 AM - StreetInsider EyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developments August 5, 2026 7:00 AM - Globe NewsWire Citi opens 90-day upside catalyst call on EyePoint August 5, 2026 6:31 AM - StreetInsider Form SCHEDULE 13G EyePoint, Inc. Filed by: VANGUARD CAPITAL MANAGEMENT LLC July 31, 2026 10:19 AM - SEC Filing Form 8-K EyePoint, Inc. For: Jul 30 July 30, 2026 7:05 AM - SEC Filing EyePoint completes enrollment in two phase 3 DME drug trials July 30, 2026 7:01 AM - StreetInsider EyePoint Completes Enrollment of Both Pivotal Phase 3 Trials of DURAVYU™ for Treatment of Diabetic Macular Edema (DME) July 30, 2026 7:00 AM - Globe NewsWire EyePoint Inc. (EYPT) PT Raised to $39 at Mizuho, 'Top Pick' July 29, 2026 6:53 AM - StreetInsider Form SCHEDULE 13G/A EyePoint, Inc. Filed by: BlackRock, Inc. July 28, 2026 4:46 PM - SEC Filing Form 144/A EyePoint, Inc. Filed by: Lurker Nancy July 22, 2026 5:05 PM - SEC Filing Form 144/A EyePoint, Inc. Filed by: Lurker Nancy July 22, 2026 1:44 PM - SEC Filing Form 144 EyePoint, Inc. Filed by: Lurker Nancy July 21, 2026 4:44 PM - SEC Filing EyePoint Pharmaceuticals settles False Claims Act case for $4.7M July 17, 2026 4:07 PM - StreetInsider Form 8-K EyePoint, Inc. For: Jul 13 July 17, 2026 4:05 PM - SEC Filing EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) July 16, 2026 7:00 AM - Globe NewsWire Stifel Starts EyePoint Inc. (EYPT) at Buy July 15, 2026 4:07 PM - StreetInsider Form 4 EyePoint, Inc. For: Jul 10 Filed by: Duker Jay S. July 14, 2026 4:08 PM - SEC Filing EyePoint Appoints Tarek S. Hassan, M.D., as Chief Strategic Science Officer July 13, 2026 7:00 AM - Globe NewsWire Cantor Fitzgerald Assumes EyePoint Inc. (EYPT) at Overweight July 8, 2026 6:14 AM - StreetInsider These 5 stocks are added to The Mizuho Top Picks List for July July 3, 2026 4:00 PM - StreetInsider Form 4 EyePoint, Inc. For: Jun 30 Filed by: Ribeiro Ramiro July 2, 2026 4:03 PM - SEC Filing Mizuho Reiterates Outperform Rating on EyePoint Inc. (EYPT) June 23, 2026 6:41 AM - StreetInsider Form 8-K EyePoint, Inc. For: Jun 18 June 22, 2026 7:05 AM - SEC Filing EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) June 16, 2026 7:00 AM - Globe NewsWire Full Article List